Purification – a bottleneck for large-scale manufacturing of oligonucleotide API?
The biopharmaceutical industry has seen a significant increase in interest in oligonucleotide-based drugs over the past five years. These drugs were originally used to treat rare diseases but are now being developed to target more common diseases and larger patient...
New mass spectrometry (MS) characterization for an accurate identification of oligonucleotide impurities
The therapeutic usage of oligonucleotide-based drugs is growing. Moving from rare diseases to chronic indications, the market demand for oligonucleotide therapeutics keeps increasing and is coupled by the emergence of new challenges related to scalability,...
On the way to greener SPPS: Replacing DMF
At Bachem, we are committed to sustainability by taking responsibility towards the environment, society and our employees. We aim to redesign our processes to minimize the use and generation of hazardous substances and reduce the environmental impact. In the...
What does it take to manufacture oligonucleotides?
Looking for more info about future trends in oligonucleotides? Listen to the podcast and hear Daniel Samson share his industry insight. He discusses capacity, scalability, cost-effectiveness, time-to-market, sustainability, and the trend toward increasingly complex...